NTT/SAP
15.9.2016 11:13:23 CEST | Business Wire | Press release
SAP SE (NYSE:SAP) and Nippon Telegraph and Telephone Corporation (NTT) (NYSE:NTT) announced today its partnership enhancement in ‘Co-Innovation’, ‘Cross-Selling of Solutions’ and ‘Global Reference’.
SAP and NTT are collaborating by integrating cutting-edge technologies. As the first project of this initiative, to support safety operation of the transportation industry, the two companies have developed a solution combining SAP’s Connected Transportation Safety (CTS) solutions, which collects and analyzes vehicle related data, with NTT’s hitoe®, sensing fabric jointly developed with Toray Industries, and NTT IoT analytics platform, which provides driver’s biological data including heart rate and mental fatigue estimate, the project aims to provide more accurate and real-time information about vehicle and driver’s condition.
In cooperation with Keifuku Bus Co., Ltd (Fukui, Japan), SAP and NTT Group will conduct a field trial from October 2016, targeting to provide service from January 2017. The companies are planning to rollout this solution in the United States and Europe as well.
“We are honored to partner with NTT group who runs the world’s biggest data centers,” said Rob Enslin, member of the Executive Board of SAP SE and president of Global Customer Operations, SAP. “This partnership brings significant impact on SAP to broaden customers’ choice upon facilitating digital transformation. The integration of NTT’s cutting-edge technologies and SAP’s revolutionary solutions will generate momentum to elevate the overall market to the next level. By closely collaborating on a global scale, NTT and SAP will continuously strengthen ties to drive the three key initiatives including Co-innovation, Global Partnership, and SAP Solution Reference Customer in a long term perspective.”
“NTT aims to contribute to business transformation of its enterprise clients by providing high value-added services with partners.” said Jun Sawada, Senior Executive Vice President of NTT, “Global partnership with SAP is a significant step for strengthening our competitiveness in the rapidly changing ICT market. Through this partnership, along with SAP’s expertise and experiences, NTT can enhance its capabilities to support our global clients, and can accelerate digital transformation of industries.”
This co-innovation effort started in Palo Alto, California and has been led by NTT Labs and SAP Labs China. SAP and NTT Group intend to continue co-innovations in various areas with new technologies and expand its partnership through marketing promotion globally.
SAP and NTT Group have agreed to advance their digital practice collaboration and have formatted a new partner for Industrial Revolution. Primary target for 2016 is to move customers to the cloud for IoT and Industry 4.0.
While the partnership is not limited to Industrial Revolution, both companies are also accelerating their collaboration around private managed cloud solutions such as SAP HANA Enterprise Cloud leveraging NTT’s world class data center network around the globe. NTT is also a S/4 HANA Adoption Pinnacle Award Winner 2016.
In addition, NTT and SAP will create a global reference which could become a universal model. NTT has been working on establishing business platform as well as IT infrastructure to create synergy within the group. To accelerate the process, NTT is going to utilize the latest SAP solutions.
About SAP
As market leader in enterprise application software, SAP (NYSE: SAP) helps companies of all sizes and industries run better. From back office to boardroom, warehouse to storefront, desktop to mobile device – SAP empowers people and organizations to work together more efficiently and use business insight more effectively to stay ahead of the competition. SAP applications and services enable more than 320,000 customers to operate profitably, adapt continuously, and grow sustainably. The company is traded under the ‘SAP’ brand on the Frankfurt Stock Exchange, the New York Stock Exchange and other major global bourses. For more information, visit www.sap.com .
Copyright© 2016 SAP SE or an SAP affiliate company. All rights reserved.
SAP,
the SAP logo and other SAP products and services mentioned herein as
well as their respective logos are trademarks or registered trademarks
of SAP SE (or an SAP affiliate company) in Germany and other countries.
Other company names, logos, product names, etc. mentioned herein are the
registered trademarks or trademarks of the companies in question.
About Nippon Telegraph and Telephone Corporation (NTT)
NTT Group delivers advanced technology and innovative solutions in
networking, software communications, and cloud computing that help
transform businesses, governments and societies around the world.
NTT
Group will deliver convenient, enriched and reliable services to support
customers as a ‘Value Partner’ that its customers will continue to
select. Today, 85% of Fortune Global 100 companies rely on NTT Group as
their business partner. NTT Group generates over $95 billion in annual
revenues, has over 240 data centers and employs more than 241,000
professionals working in 87 countries. For more information, visit www.ntt-global.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160915005612/en/
Contact:
Media Contacts
SAP Global PR
contact
Jason Loesche
j.loesche@sap.com
or
SAP
Japan Co., Ltd.
Kaori Suzuki, +81-(3) 6737-3880 (division
switchboard); +81-80-1007-5933 (direct line)
Public Relations
kaori.suzuki@sap.com
or
Nippon
Telegraph and Telephone Corporation
Public Relations Office
ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom